JP2010522728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522728A5 JP2010522728A5 JP2010500302A JP2010500302A JP2010522728A5 JP 2010522728 A5 JP2010522728 A5 JP 2010522728A5 JP 2010500302 A JP2010500302 A JP 2010500302A JP 2010500302 A JP2010500302 A JP 2010500302A JP 2010522728 A5 JP2010522728 A5 JP 2010522728A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- product
- infection
- sepsis
- rscd6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010040047 Sepsis Diseases 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 15
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 239000012678 infectious agent Substances 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000009182 Parasitemia Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 206010058874 Viraemia Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 description 20
- 229920006008 lipopolysaccharide Polymers 0.000 description 20
- 230000027455 binding Effects 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 6
- 102100024210 CD166 antigen Human genes 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 108091005725 scavenger receptor cysteine-rich superfamily Proteins 0.000 description 4
- 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 101800000483 Surface protein gp120 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 229920000392 Zymosan Polymers 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108091006004 biotinylated proteins Proteins 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 241000269627 Amphiuma means Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 102000000185 SRCR domains Human genes 0.000 description 1
- 108050008568 SRCR domains Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003410 b-1a b lymphocyte Anatomy 0.000 description 1
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 108010066312 streptavidin-tricolor Proteins 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200700893 | 2007-03-28 | ||
| ES200700893 | 2007-03-28 | ||
| PCT/ES2008/000177 WO2008119851A1 (es) | 2007-03-28 | 2008-03-27 | Producto proteico para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010522728A JP2010522728A (ja) | 2010-07-08 |
| JP2010522728A5 true JP2010522728A5 (https=) | 2011-05-06 |
| JP5583575B2 JP5583575B2 (ja) | 2014-09-03 |
Family
ID=39807834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010500302A Expired - Fee Related JP5583575B2 (ja) | 2007-03-28 | 2008-03-27 | 感染症と関連炎症過程の治療のためのタンパク質生成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8691752B2 (https=) |
| EP (1) | EP2143436B1 (https=) |
| JP (1) | JP5583575B2 (https=) |
| CA (1) | CA2681828A1 (https=) |
| ES (1) | ES2550389T3 (https=) |
| WO (1) | WO2008119851A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008119851A1 (es) * | 2007-03-28 | 2008-10-09 | Universidad De Barcelona | Producto proteico para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados |
| JP2014516046A (ja) * | 2011-05-26 | 2014-07-07 | フンダシオ・クリニック・ペル・ア・ラ・レセルカ・ビオメディカ | がん若しくは腫瘍の治療用の又はアジュバントとして使用される可溶性タンパク質ｃｄ５又はｃｄ６ |
| JP2019535834A (ja) | 2016-11-18 | 2019-12-12 | ユニベルシタ デ バルセロナ | 感染症及び関連炎症プロセスの処置のためのｃｄ６及びイミペネムの併用療法 |
| ES2953362T3 (es) | 2018-03-13 | 2023-11-10 | Sepsia Therapeutics S L | Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6315999B1 (en) * | 1989-08-10 | 2001-11-13 | Solvay, S.A. | Pharmaceutical product for the treatment of sepsis |
| WO1993019772A1 (en) | 1992-04-06 | 1993-10-14 | North Shore University Hospital Research Corporation | A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen |
| CA2175247A1 (en) | 1993-11-02 | 1995-05-11 | Barton F. Haynes | Cd6 ligand |
| US6290948B1 (en) * | 1996-05-14 | 2001-09-18 | Smithkline Beecham Corporation | Method of treating sepsis and ARDS using chamohine beta-10 |
| CA2268085A1 (en) * | 1996-10-22 | 1998-04-30 | Go Wakabayashi | Sepsis remedy comprising anti-il-8 antibody as active ingredient |
| US6172220B1 (en) * | 1997-01-21 | 2001-01-09 | Board Of Regents Of University Of Nebraska | Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis |
| WO2000023101A1 (en) * | 1998-10-22 | 2000-04-27 | Eli Lilly And Company | Methods for treating sepsis |
| US20030114377A1 (en) * | 1998-11-18 | 2003-06-19 | Kirkland Theo N. | Inhibition therapy for septic shock with mutant CD14 |
| US6673346B1 (en) * | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
| US20020006915A1 (en) | 2000-02-15 | 2002-01-17 | Mack Strong Vivian E. | Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation |
| EP1278749B1 (en) * | 2000-04-25 | 2005-01-26 | Bristol-Myers Squibb Company | USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| ES2334773T3 (es) * | 2001-05-16 | 2010-03-16 | Yeda Research And Development Co. Ltd. | Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis. |
| US6729735B2 (en) | 2001-06-28 | 2004-05-04 | Plx, Inc. | Lateral transfer retroreflector assembly and method of assembling the same |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| WO2008119851A1 (es) * | 2007-03-28 | 2008-10-09 | Universidad De Barcelona | Producto proteico para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados |
| ES2336752B1 (es) * | 2008-06-20 | 2011-05-11 | Hospital Clinic I Provincial De Barcelona | Composiciones farmaceuticas de cd5. |
-
2008
- 2008-03-27 WO PCT/ES2008/000177 patent/WO2008119851A1/es not_active Ceased
- 2008-03-27 US US12/593,140 patent/US8691752B2/en active Active - Reinstated
- 2008-03-27 EP EP08750412.2A patent/EP2143436B1/en active Active
- 2008-03-27 JP JP2010500302A patent/JP5583575B2/ja not_active Expired - Fee Related
- 2008-03-27 ES ES08750412.2T patent/ES2550389T3/es active Active
- 2008-03-27 CA CA002681828A patent/CA2681828A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Immunopathogenesis and treatment of cytokine storm in COVID-19 | |
| Chu et al. | Interferon‐γ regulates susceptibility to collagen‐induced arthritis through suppression of interleukin‐17 | |
| Okeke et al. | CD4+ CD25+ regulatory T cells attenuate lipopolysaccharide-induced systemic inflammatory responses and promotes survival in murine Escherichia coli infection | |
| Mizutani et al. | Interleukin‐33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE‐mediated airway inflammation and remodelling in mice | |
| Jodele et al. | Tackling COVID‐19 infection through complement‐targeted immunotherapy | |
| Xu et al. | Interleukin‐33 contributes to ILC 2 activation and early inflammation‐associated lung injury during abdominal sepsis | |
| Liu et al. | Macrophages as effectors of acute and chronic allograft injury | |
| Carlier et al. | The epithelial barrier and immunoglobulin A system in allergy | |
| EP3530282A1 (en) | Therapeutic methods | |
| De Vooght et al. | Neutrophil and eosinophil granulocytes as key players in a mouse model of chemical-induced asthma | |
| Takenaka et al. | Antibodies to MHC class II molecules induce autoimmunity: critical role for macrophages in the immunopathogenesis of obliterative airway disease | |
| CN111870688A (zh) | ACE2蛋白与IL-6或TNFα拮抗剂组合及其应用 | |
| Lélu et al. | Viral delivery of IL-7 is a potent immunotherapy stimulating innate and adaptive immunity and confers survival in sepsis models | |
| Berghmans et al. | Rescue from acute neuroinflammation by pharmacological chemokine-mediated deviation of leukocytes | |
| JP2010522728A5 (https=) | ||
| Nakayama et al. | Novel antiviral activity of chemokines | |
| US8221988B2 (en) | Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation | |
| Zhang et al. | The attenuation of Th1 and Th17 responses via autophagy protects against methicillin-resistant Staphylococcus aureus-induced sepsis | |
| Jiang et al. | Recombinant human interleukin 17A enhances the anti‐Candida effect of human oral mucosal epithelial cells by inhibiting Candida albicans growth and inducing antimicrobial peptides secretion | |
| Kozicky et al. | Intravenous immunoglobulin (IVIg) or IVIg‐treated macrophages reduce DSS‐induced colitis by inducing macrophage IL‐10 production | |
| Kyo et al. | Endogenous interleukin‐6, but not tumor necrosis factor α, contributes to the development of toll‐like receptor 4/myeloid differentiation factor 88–mediated acute arthritis in mice | |
| Chintakuntlawar et al. | Adenovirus type 37 keratitis in the C57BL/6J mouse | |
| Pawankar et al. | Mast cell-IgE-and mast cell-structural cell interactions in allergic airway disease | |
| Jeon et al. | Symbiotic microbiome Staphylococcus epidermidis restricts IL-33 production in allergic nasal epithelium via limiting the cellular necroptosis | |
| Kusano et al. | A novel anti‐histone H1 monoclonal antibody, SSV monoclonal antibody, improves lung injury and survival in a mouse model of lipopolysaccharide‐induced sepsis‐like syndrome |